Raul Altman

Summary

Country: Argentina

Publications

  1. pmc Simple and rapid assay for effect of the new oral anticoagulant (NOAC) rivaroxaban: preliminary results support further tests with all NOACs
    Raul Altman
    Centro de Trombosis de Buenos Aires, Viamonte 2008, Buenos Aires 1056, Argentina
    Thromb J 12:7. 2014
  2. pmc New oral anticoagulants: are coagulation units still required?
    Raul Altman
    Centro de Trombosis Buenos Aires, Viamonte 2008, Buenos Aires 1056, Argentina
    Thromb J 12:3. 2014
  3. pmc Thrombin generation by activated factor VII on platelet activated by different agonists. Extending the cell-based model of hemostasis
    Raul Altman
    Centro de Trombosis de Buenos Aires, Buenos Aires, Argentina
    Thromb J 4:5. 2006
  4. pmc Acute coronary disease Athero-Inflammation: Therapeutic approach
    Raul Altman
    Centro de Trombosis de Buenos Aires and Catedra de Magister en Trombosis, Facultad de Medicina, Universidad Nacional de Tucuman, Argentina
    Thromb J 1:2. 2003
  5. ncbi request reprint Effect of sodium arachidonate on thrombin generation through platelet activation--inhibitory effect of aspirin
    R Altman
    Centro de Trombosis de Buenos Aires, Argentina
    Thromb Haemost 84:1109-12. 2000
  6. pmc Bleeding tendency in dual antiplatelet therapy with aspirin/clopidogrel: rescue of the template bleeding time in a single-center prospective study
    Raul Altman
    Centro de Trombosis de Buenos Aires, Buenos Aires, Argentina
    Thromb J 10:3. 2012
  7. pmc Battle of oral anticoagulants in the field of atrial fibrillation scrutinized from a clinical practice (the real world) perspective
    Raul Altman
    Centro de Trombosis de Buenos Aires, Viamonte 2008, 1056 Buenos Aires, Argentina
    Thromb J 9:12. 2011
  8. pmc The hemostatic profile of recombinant activated factor VII. Can low concentrations stop bleeding in off-label indications?
    Raul Altman
    Centro de Trombosis de Buenos Aires, Viamonte 2008, 1056 Buenos Aires, Argentina
    Thromb J 8:8. 2010
  9. pmc Anithrombotic prevention in vascular disease: bases for a new strategy in antithrombotic therapy
    Raul Altman
    Centro de Trombosis de Buenos Aires, Buenos Aires, Argentina
    Thromb J 5:11. 2007
  10. ncbi request reprint Recombinant factor VIIa reverses the inhibitory effect of aspirin or aspirin plus clopidogrel on in vitro thrombin generation
    R Altman
    Centro de Trombosis de Buenos Aires, Buenos Aires, Argentina
    J Thromb Haemost 4:2022-7. 2006

Collaborators

Detail Information

Publications19

  1. pmc Simple and rapid assay for effect of the new oral anticoagulant (NOAC) rivaroxaban: preliminary results support further tests with all NOACs
    Raul Altman
    Centro de Trombosis de Buenos Aires, Viamonte 2008, Buenos Aires 1056, Argentina
    Thromb J 12:7. 2014
    ..New oral anticoagulant (NOAC) drugs are known to influence the results of some routine hemostasis tests. Further data are needed to enable routine assessment of the effects of NOAC on clotting parameters in some special circumstances...
  2. pmc New oral anticoagulants: are coagulation units still required?
    Raul Altman
    Centro de Trombosis Buenos Aires, Viamonte 2008, Buenos Aires 1056, Argentina
    Thromb J 12:3. 2014
    ..Therefore, we still recommend the use of anticoagulation units for monitoring during treatment with the new oral anticoagulants. ..
  3. pmc Thrombin generation by activated factor VII on platelet activated by different agonists. Extending the cell-based model of hemostasis
    Raul Altman
    Centro de Trombosis de Buenos Aires, Buenos Aires, Argentina
    Thromb J 4:5. 2006
    ..Platelet activation is crucial in normal hemostasis. Using a clotting system free of external tissue factor, we investigated whether activated Factor VII in combination with platelet agonists increased thrombin generation (TG) in vitro...
  4. pmc Acute coronary disease Athero-Inflammation: Therapeutic approach
    Raul Altman
    Centro de Trombosis de Buenos Aires and Catedra de Magister en Trombosis, Facultad de Medicina, Universidad Nacional de Tucuman, Argentina
    Thromb J 1:2. 2003
    ....
  5. ncbi request reprint Effect of sodium arachidonate on thrombin generation through platelet activation--inhibitory effect of aspirin
    R Altman
    Centro de Trombosis de Buenos Aires, Argentina
    Thromb Haemost 84:1109-12. 2000
    ..Sodium arachidonate was used in this study to determine its capacity to generate thrombin through platelet activation. Whether aspirin prevent this effect was also investigated...
  6. pmc Bleeding tendency in dual antiplatelet therapy with aspirin/clopidogrel: rescue of the template bleeding time in a single-center prospective study
    Raul Altman
    Centro de Trombosis de Buenos Aires, Buenos Aires, Argentina
    Thromb J 10:3. 2012
    ..The challenge is to identify patients at risk of bleeding. This study sought to characterize bleeding tendency in patients treated with aspirin and clopidogrel...
  7. pmc Battle of oral anticoagulants in the field of atrial fibrillation scrutinized from a clinical practice (the real world) perspective
    Raul Altman
    Centro de Trombosis de Buenos Aires, Viamonte 2008, 1056 Buenos Aires, Argentina
    Thromb J 9:12. 2011
    ....
  8. pmc The hemostatic profile of recombinant activated factor VII. Can low concentrations stop bleeding in off-label indications?
    Raul Altman
    Centro de Trombosis de Buenos Aires, Viamonte 2008, 1056 Buenos Aires, Argentina
    Thromb J 8:8. 2010
    ..Since thrombin is the main hemostatic agent, this study investigated the effect of rFVIIa and tissue factor (TF) on thrombin generation (TG) in vitro...
  9. pmc Anithrombotic prevention in vascular disease: bases for a new strategy in antithrombotic therapy
    Raul Altman
    Centro de Trombosis de Buenos Aires, Buenos Aires, Argentina
    Thromb J 5:11. 2007
    ..Although some preliminary data have been already published, to confirm the potential benefit of anti-inflammatory drugs in acute coronary syndromes large prospective double-bind randomized trials are necessary...
  10. ncbi request reprint Recombinant factor VIIa reverses the inhibitory effect of aspirin or aspirin plus clopidogrel on in vitro thrombin generation
    R Altman
    Centro de Trombosis de Buenos Aires, Buenos Aires, Argentina
    J Thromb Haemost 4:2022-7. 2006
    ..This study investigated: (a) whether a regimen of aspirin or clopidogrel plus aspirin significantly inhibited platelet thrombin generation (TG); and (b) the reversal of this inhibition by recombinant activated factor VII (rFVIIa)...
  11. ncbi request reprint No causal association between inflammation and Chlamydia pneumoniae in patients with chronic ischemic arterial disease
    Raul Altman
    Centro de Trombosis de Buenos Aires, Argentina
    Inflammation 26:25-30. 2002
    ..These results suggest that no causal association exists between inflammation and C. pneumoniae. A highly significant correlation between C-reactive protein and fibrinogen levels was found...
  12. ncbi request reprint Does combined clopidogrel and statin therapy benefit patients with non-ST-elevation myocardial infarction?
    Raul Altman
    Faculty of Medicine, National University of Tucuman, Argentina
    Nat Clin Pract Cardiovasc Med 2:558-9. 2005
  13. ncbi request reprint Efficacy assessment of meloxicam, a preferential cyclooxygenase-2 inhibitor, in acute coronary syndromes without ST-segment elevation: the Nonsteroidal Anti-Inflammatory Drugs in Unstable Angina Treatment-2 (NUT-2) pilot study
    Raul Altman
    Centro de Trombosis de Buenos Aires, Catedra de Magister en Trombosis, Facultad de Medicina de Tucuman, Buenos Aires, Argentina
    Circulation 106:191-5. 2002
    ....
  14. ncbi request reprint Abciximab does not inhibit the increase of thrombin generation produced in platelet-rich plasma in vitro by sodium arachidonate or tissue factor
    Raul Altman
    Centro de Trombosis de Buenos Aires, School of Medicine, University of Buenos Aires, Argentina
    Clin Appl Thromb Hemost 11:271-7. 2005
    ..Abciximab, which affects non-aspirinated, nonactivated PRP weakly, has no effect on AA or TF in activated control PRP or in vivo aspirinated PRP...
  15. ncbi request reprint Fibrinogen: intra-individual variability in patients with arterial disease and in patients with cardiac valve replacements
    Jorge Rouvier
    Buenos Aires Thrombosis Center, Buenos Aires, Argentina
    Isr Med Assoc J 4:992-5. 2002
    ..Elevated fibrinogen, considered an independent risk factor for coronary disease, stratifies an individual as high risk for coronary disease. A risk marker requires little intra-individual variability during a long period...
  16. ncbi request reprint Efficacy of unfractionated heparin, low molecular weight heparin and both combined for releasing total and free tissue factor pathway inhibitor
    R Altman
    Centro de Trombosis de Buenos Aires, Argentina
    Haemostasis 28:229-35. 1998
    ..01). We concluded that at comparable therapeutic doses, subcutaneous UFHvar released more free TFPI than LMWH and ComHep. A synergism between LMWH and low dose of UFH was found in 4-, 6- and 12-hour blood samples...